Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
View Patent ↗OP/BMP morphogen may be combined with GDNF/NGF neurotrophic factors to promote the survival or growth, or inhibit the death or degeneration, of mammalian cells, particularly neural cells, which express OP/BMP-activated serine/threonine kinase receptors and GDNF/NGF-activated tyrosine kinase receptors. Also disclosed are methods for the treatment of such cells, including treatments for mammals afflicted with, or at imminent risk of, damage or injury to, such cells, as well as new pharmaceutical preparations for such treatments.
1. A method for promoting the survival or growth of mammalian peripheral nervous system neural cells in vivo, wherein said neural cells express an OP/BMP-activated serine/threonine kinase receptor and a GDNF-activated tyrosine kinase receptor, comprising
contacting said cells with an effective concentration of a preparation comprising
(a) a GDNF neurotrophic factor, and
(b) an OP/BMP morphogen comprising an amino acid sequence having at least 70% homology or 60% identity with the C-terminal seven cysteine skeleton of human OP-1, wherein said OP/BMP morphogen can induce ectopic bone;
wherein said OP/BMP morphogen and said GDNF neurotrophic factor act synergistically to promote survival of mammalian peripheral nervous system neural cells.
2. The method of claim 1 , wherein said OP/BMP morphogen comprises an amino acid sequence having at least 80% homology with the C-terminal seven-cysteine skeleton of human OP-1.
3. The method of claim 1 , wherein said OP/BMP morphogen comprises an amino acid sequence having at least 90% homology with the C-terminal seven-cysteine skeleton of human OP-1.
4. The method of claim 1 , wherein said OP/BMP morphogen comprises an amino acid sequence having at least 70% identity with the C-terminal seven-cysteine skeleton of human OP-1.
5. The method of claim 1 , wherein said OP/BMP morphogen is selected from the group consisting of OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6, and BMP9.
6. The method as of claim 1 , wherein said GDNF neurotrophic factor is human GDNF.
7. The method of claim 1 , wherein said preparation comprises between 1 ng/ml and 100 ng/ml of said OP/BMP morphogen.
8. The method of claim 1 , wherein said preparation comprises between 1 ng/ml and 100 ng/ml of said GDNF neurotrophic factor.
9. The method of claim 1 wherein said preparation comprises between 1 ng/ml and 100 ng/ml of said OP/BMP morphogen and between 1 ng/ml and 100 ng/ml of said GDNF neurotrophic factor.
10. The method of claim 1 , wherein said OP/BMP morphogen is op-1.